Evidence map›Paper›PMID 22125655›Full record

ArticleThe Journal of clinical and aesthetic dermatology2011

Tretinoin: A Review of Its Anti-inflammatory Properties in the Treatment of Acne.

Nicholas Schmidt, Eugene H Gans

Registry-linked trialAbstract read
In one paragraph

Article in The Journal of clinical and aesthetic dermatology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06358677 (A Phase II, Randomized, Double-Blind, Split-Face of Topical Tretinoin Prophylaxis for Anti-EGFR Induced Skin Toxicity in Patients With Solid Tumors), which is not on this map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06358677 phase2recruitingnot on this mapstarted 2025, after this paper: background citation

A Phase II, Randomized, Double-Blind, Split-Face of Topical Tretinoin Prophylaxis for Anti-EGFR Induced Skin Toxicity in Patients With Solid Tumors

TypeinterventionalSponsorUniversity of UtahRan2025 to 2029Enrolled25ConditionsMetastatic Solid Tumor, Locally Advanced Solid TumorArmsTopical Tretinoin, Placebo
3 · Its place in the literature

Who cites it

24 citing papers in PubMed.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. BMAL1 regulatesInternational journal of biological sciences · 2022
    Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Nicholas SchmidtMedicis Pharmaceutical Corporation, Scottsdale, Arizona.
Eugene H Gans

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tretinoin has been primarily used for the early stages of acne because of its proven comedolytic end benefits. This article reviews and updates the collective body of evidence of tretinoin in the treatment of acne, which suggests that this drug also possesses a broad range of acne-related immunomodulating properties that are capable of disrupting and hindering the various stages of the inflammatory cascade and the production of proinflammatory factors associated with it.

Identifiers

PMID22125655
PMCPMC3225141

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.